Azitra, Inc. (NYSEAMERICAN:AZTR) Stock Short Interest Declines 65.7%

Azitra, Inc. (NYSEAMERICAN:AZTR) saw a large drop in short interest during the month of September. As of September 30th, there was short interest totaling 240,809 shares, a drop of 65.7% from the September 15th total of 701,345 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily volume of 889,711 shares, the short-interest ratio is currently 0.3 days.

Azitra Stock Down 1.8%

Shares of AZTR traded down $0.00 during trading hours on Wednesday, reaching $0.07. 2,670,554 shares of the company traded hands, compared to its average volume of 856,291. The stock’s fifty day moving average is $0.15 and its 200 day moving average is $0.18. Azitra has a 1-year low of $0.05 and a 1-year high of $1.09.

Azitra (NYSEAMERICAN:AZTR) last released its earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.05). On average, equities research analysts expect that Azitra will post -0.20 earnings per share for the current year.

About Azitra

Azitra, Inc is a clinical-stage biotechnology company focused on developing live biotherapeutic products for dermatological conditions. The company uses microbiome science and genetic engineering to develop beneficial bacteria designed for topical application to the skin.

Azitra’s research programs have focused on conditions including atopic dermatitis, acne vulgaris and other skin disorders associated with impaired barrier function or microbial imbalance. Its pipeline has included engineered strains of skin-associated bacteria intended to deliver therapeutic proteins or other biological effects directly to affected areas.

The company was founded in 2014 and is based in New Haven, Connecticut.